English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
ESG Reports
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
2025-02-05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
2025-01-07
VOLUNTARY ANNOUNCEMENT – APPROVAL FROM CDE FOR JSKN003 TO INITIATE A PHASE III CLINICAL STUDY FOR TREATMENT OF OC
2024-12-27
VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY CDE FOR A PHASE I/II CLINICAL TRIAL OF JSKN033
2024-12-24
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
2024-12-05
Next Day Disclosure Return
2024-11-29
VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES ON A PHASE I/II CLINICAL TRIAL OF JSKN033 FOR PRESENTATION AT SITC 2024
2024-11-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
2024-11-05
Next Day Disclosure Return
2024-10-30
Next Day Disclosure Return
2024-10-29
1
2
3
4
5
PREV
2/27
NEXT